Wide areas of the pharmaceutical industry are ripe for enhancement, as examples from the industry’s top innovators reflect.

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel ...

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...

The model has uncovered a hidden layer of molecular code that shapes biological organization, adding new dimensions of ...

The company is developing generative AI methods to design proteins from scratch, with applications in drug discovery and ...

Backed by influencial names in the life sciences industry, Latent Labs offers an AI platform to accelerate and improve drug ...